View Rule

View EO 12866 Meetings Printer-Friendly Version     Download RIN Data in XML
HHS/SAMHSA RIN: 0930-AA22 Publication ID: Fall 2016 
Title: Medication Assisted Treatment for Opioid Use Disorders Reporting Requirements 
Abstract:

 

On July 8, 2016, SAMHSA finalized a rule to increase access to buprenorphine and the combination buprenorphine/naloxone (Medication Assisted Treatment for Opioid Use Disorders).  Concurrently with this final rule, SAMHSA issued a Supplemental Notice of Proposed Rulemaking seeking further comment on reporting provisions that would apply to physicians prescribing buprenorphine for up to 275 patients.

 

 

 

 
Agency: Department of Health and Human Services(HHS)  Priority: Economically Significant 
RIN Status: Previously published in the Unified Agenda Agenda Stage of Rulemaking: Final Rule Stage 
Major: Yes  Unfunded Mandates: No 
CFR Citation: 42 CFR 8   
Legal Authority: 21 U.S.C. 823(g)(2)   
Legal Deadline:  None
Timetable:
Action Date FR Cite
NPRM  03/30/2016  81 FR 17639   
NPRM Comment Period End  05/31/2016 
Final Action  11/00/2016 
Regulatory Flexibility Analysis Required: Undetermined  Government Levels Affected: Federal, Local, State, Tribal 
Federalism: No 
Included in the Regulatory Plan: No 
RIN Data Printed in the FR: No 
Agency Contact:
Brian Altman
Legislative Director
Department of Health and Human Services
Substance Abuse and Mental Health Services Administration
1 Choke Cherry Road,
Rockville, MD 02857
Phone:240 276-2009
Email: brian.altman@samhsa.gov